

















| | | | |
|--|--|-------------|-------------|
| 4'-Bromomethyl-2-biphenylcarbonitrile Bromo OTBN) |  | 114772-54-2 | Sartans |
| 4'-[(2-Butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]biphenyl-2-carbonitrile (Cyano-Irbesartan) |  | 138401-24-8 | Irbesartan |
| 4'-((2-Butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-yl)methyl)biphenyl-2-carbonitrile |  | 114772-55-3 | Losartan |
| (1-((2'-(1H-Tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol |  | 114798-26-4 | Losartan |
| L-Valine, N-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-, phenylmethyl ester HCl |  | 137864-23-4 | Valsartan |
| L-Valine, N-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-N-(1-oxopentyl)-, phenylmethyl ester |  | 137864-22-3 | Valsartan |
| L-Valine, N-(1-oxopentyl)-N-[(2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-, phenylmethyl ester |  | 137863-20-8 | Valsartan |
| 2-Cyano-4'-(2'n-propyl-4-methyl-6'-(1-methylbenzimidazol-2'-yl)methyl)biphenyl |  | 144702-27-2 | Telmisartan |



| | | | |
|--|---|-------------|----------------|
| Methyl 4'-[[2-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)benzimidazol-1-yl]methyl]biphenyl-2-carboxylate |  | 528560-93-2 | Telmisartan |
| 2-(n-Dibutylamino)-1-(2,7-dichloro-9H-fluoren-4-yl)ethanol |  | 69759-61-1 | Lumefantrine |
| (S)-2-((2-Amino-6-oxo-1,6-dihydropurin-9-yl)methoxy)ethyl 2-(benzyloxycarbonyl)-3-methylbutanoate |  | 124832-31-1 | Valacyclovir |
| N-Carbobenzyloxy-L-valinyl-gancyclovir |  | 194154-40-0 | Valgancyclovir |
| 2-(4-Hydroxyphenyl)acetonitrile |  | 14191-95-8 | Desvenlafaxine |
| 2-(1-Hydroxycyclohexyl)-2-(4-hydroxyphenyl)acetonitrile |  | 918344-20-4 | Desvenlafaxine |

Calyx Chemicals and Pharmaceuticals Limited

Reg. Office: Unit No.110, Marwah's Complex, Krishanlal Marwah Marg, Off. Saki Vihar Road,
Andheri (East), Mumbai - 400072, Maharashtra, India.
Tel: +91-22-28571191 Fax: +91-22-66466416

USA Contact: 11728 E. Imperial Highway, Norwalk, CA 90650, Tel - 213-291-7773

Email: sales@calyxindia.com, crams@calyxindia.com, sales@calyxusa.com, crams@calyxusa.com, www.calyxindia.com

Disclaimer: "Calyx Chemicals and Pharmaceuticals Limited (the "Company") is proposing to make, subject to receipt of requisite approvals, market conditions and other considerations, an Initial Public Offering of its equity shares (the "IPO") and has filed the Draft Red Herring Prospectus (the "DRHP") with the Securities and Exchange Board of India ("SEBI"). The DRHP is available on the website of SEBI at www.sebi.gov.in, the website of the BRLMs, i.e. PL Capital Markets Private Limited at www.plindia.com and YES Bank Limited at www.yesbank.in and is also available on the website of the Company at www.calyx-pharma.com. Potential investors should note that investment in equity shares involves a degree of risk. For details, please refer to the DRHP, including the section titled "Risk Factors" of the DRHP. This publicity material does not constitute an offer of securities in any jurisdiction, including the United States of America ("USA"). Securities may not be offered or sold in the USA without registration under the U.S. Securities Act of 1933 as amended, or an exemption therefrom. The Company has not and does not intend to offer any securities to the public in the USA".